{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:14:13Z","timestamp":1762503253883,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ctro.2022.06.008","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T20:31:50Z","timestamp":1656361910000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The cost of elective nodal coverage in prostate cancer: Late quality of life outcomes and dosimetric analysis with 0, 45 or 54\u00a0Gy to the pelvis"],"prefix":"10.1016","volume":"36","author":[{"given":"Garrett L.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer G.","family":"Jhavar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul S","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendall P.","family":"Hammonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ctro.2022.06.008_b0005","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2022.06.008_b0010","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/0360-3016(88)90225-8","article-title":"Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77\u201306","volume":"15","author":"Asbell","year":"1988","journal-title":"Int J Radiat Oncol"},{"issue":"34","key":"10.1016\/j.ctro.2022.06.008_b0015","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.10.5171","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? preliminary results of GETUG-01","volume":"25","author":"Pommier","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2022.06.008_b0020","article-title":"Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy","volume":"9","author":"McDonald","year":"2014","journal-title":"Radiat Oncol Lond Engl"},{"issue":"3","key":"10.1016\/j.ctro.2022.06.008_b0025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijrobp.2018.10.003","article-title":"Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL)","volume":"103","author":"Dearnaley","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.06.008_b0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","article-title":"Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial","volume":"145","author":"Murthy","year":"2020","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ctro.2022.06.008_b0035","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ijrobp.2009.08.043","article-title":"Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer","volume":"78","author":"Deville","year":"2010","journal-title":"Int J Radiat Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2022.06.008_b0040","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctro.2022.06.008_b0045","doi-asserted-by":"crossref","first-page":"e0141639","DOI":"10.1371\/journal.pone.0141639","article-title":"Quality of life after post-prostatectomy intensity modulated radiation therapy: pelvic nodal irradiation is not associated with worse bladder, bowel, or sexual outcomes","volume":"10","author":"Melotek","year":"2015","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.ctro.2022.06.008_b0050","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.ijrobp.2020.07.031","article-title":"Toxicity of pelvic lymph node irradiation with intensity modulated radiation therapy for high-risk and locally advanced prostate cancer: a national population-based study using patient-reported outcomes","volume":"108","author":"Parry","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.06.008_b0055","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3109\/0284186X.2015.1127417","article-title":"Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer","volume":"55","author":"Lilleby","year":"2016","journal-title":"Acta Oncol Stockh Swed"},{"issue":"19","key":"10.1016\/j.ctro.2022.06.008_b0060","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.296.19.2329","article-title":"Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial","volume":"296","author":"Thompson","year":"2006","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ctro.2022.06.008_b0065","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.2008.18.9563","article-title":"Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96\u201302\/AUO AP 09\/95","volume":"27","author":"Wiegel","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9858","key":"10.1016\/j.ctro.2022.06.008_b0070","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctro.2022.06.008_b0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cncr.27712","article-title":"Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy","volume":"119","author":"Moghanaki","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2022.06.008_b0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00066-017-1215-9","article-title":"Postoperative radiotherapy for prostate cancer : Morbidity of local-only or local-plus-pelvic radiotherapyPostoperative Strahlentherapie beim Prostatakarzinom: Morbidit\u00e4t nach lokaler Radiatio vs. lokaler Radiatio und Beckenbestrahlung","volume":"194","author":"Waldstein","year":"2018","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"issue":"1","key":"10.1016\/j.ctro.2022.06.008_b0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.eururo.2017.10.009","article-title":"Multi-institutional evaluation of elective nodal irradiation and\/or androgen deprivation therapy with postprostatectomy salvage radiotherapy for prostate cancer","volume":"74","author":"Ramey","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ctro.2022.06.008_b0090","doi-asserted-by":"crossref","first-page":"e0215057","DOI":"10.1371\/journal.pone.0215057","article-title":"Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: a propensity score matching analysis","volume":"14","author":"Song","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctro.2022.06.008_b0095","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijrobp.2007.02.035","article-title":"Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients","volume":"69","author":"Spiotto","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2022.06.008_b0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2013.08.021","article-title":"Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: toxicity and matched case comparison with postoperative prostate bed-only radiotherapy","volume":"109","author":"Van Praet","year":"2013","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2022.06.008_b0105","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ijrobp.2011.04.041","article-title":"Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy","volume":"82","author":"Deville","year":"2012","journal-title":"Int J Radiat Oncol"},{"issue":"1063","key":"10.1016\/j.ctro.2022.06.008_b0110","doi-asserted-by":"crossref","first-page":"20150985","DOI":"10.1259\/bjr.20150985","article-title":"No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy","volume":"89","author":"Jereczek-Fossa","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctro.2022.06.008_b0115","doi-asserted-by":"crossref","unstructured":"Moghanaki D, Urdaneta AI, Karlin JD, Koontz BF, Anscher MS. Management of postprostatectomy biochemical relapse with salvage radiotherapy: results of an international survey. Am J Clin Oncol 2016;39.","DOI":"10.1097\/COC.0000000000000020"},{"issue":"10338","key":"10.1016\/j.ctro.2022.06.008_b0120","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2022.06.008_b0125","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ctro.2022.06.008_b0130","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.juro.2011.04.085","article-title":"Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer","volume":"186","author":"Chang","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.ctro.2022.06.008_b0135","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","article-title":"Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors","volume":"76","author":"Szymanski","year":"2010","journal-title":"Urology"},{"issue":"21","key":"10.1016\/j.ctro.2022.06.008_b0140","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1200\/JCO.18.02237","article-title":"Treatment-related toxicity using prostate-only versus prostate and pelvic lymph node intensity-modulated radiation therapy: a national population-based study","volume":"37","author":"Parry","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctro.2022.06.008_b0145","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.juro.2010.02.013","article-title":"Health related quality of life for men treated for localized prostate cancer with long-term followup","volume":"183","author":"Huang","year":"2010","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ctro.2022.06.008_b0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the expanded prostate cancer index composite short form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ctro.2022.06.008_b0155","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.ctro.2022.06.008_b0160","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","article-title":"An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94\u201313, with emphasis on unexpected hormone\/radiation interactions","volume":"69","author":"Lawton","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2022.06.008_b0165","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijrobp.2015.09.020","article-title":"Outcome according to elective pelvic radiation therapy in patients with high-risk localized prostate cancer: a secondary analysis of the GETUG 12 Phase 3 randomized trial","volume":"94","author":"Blanchard","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctro.2022.06.008_b0170","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.ijrobp.2021.01.034","article-title":"Underascertainment of clinically meaningful symptoms during prostate cancer radiation therapy-does this vary by patient characteristics?","volume":"110","author":"Sud","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.06.008_b0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0360-3016(00)01365-1","article-title":"Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population","volume":"49","author":"Hanlon","year":"2001","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctro.2022.06.008_b0180","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ijrobp.2008.12.082","article-title":"Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma","volume":"75","author":"Aizer","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.06.008_b0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1748-717X-3-3","article-title":"Does Intensity Modulated Radiation Therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?","volume":"3","author":"Guckenberger","year":"2008","journal-title":"Radiat Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2022.06.008_b0190","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.ijrobp.2018.08.052","article-title":"Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG oncology\/RTOG 0534 SPPORT Trial","volume":"102","author":"Pollack","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.06.008_b0195","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"10.1016\/j.ctro.2022.06.008_b0200","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:09:56Z","timestamp":1762502996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630822000532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":40,"alternative-id":["S2405630822000532"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2022.06.008","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost of elective nodal coverage in prostate cancer: Late quality of life outcomes and dosimetric analysis with 0, 45 or 54\u00a0Gy to the pelvis","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2022.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}